Audit: QRS - Cat’s Claw for Health & Longevity

Audit conducted on 11/09/2026 05:47 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every span traced to ER source: protocol approaches/doses to ER Therapeutic Protocol, time-to-effect to ER Practical Considerations, gates to Key Interactions & Contraindications, markers and cadence to Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	ER’s “⚠️ Conflicted” markers carried as “(conflicted)” on both the High benefit and the CYP3A4 risk; “Safety reporting is reassuring but shallow” kept verbatim in the lede.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain in the stop gate, interactions remain in the caution gate; no tier or severity migration observed.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	ER Benefit-Modifying Factors and Risk-Modifying Factors contribute nothing to the QRS; each QRS section draws only from its mandated ER section.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only brand names C-Med-100 / AC-11 appear (line 471), matching ER Therapeutic Protocol line 333 for the same preparation. No PMIDs, NCT IDs, or investigator names.
1.6	The QRS does not introduce new attributions.	🟢	ER attributions (Keplinger, Immodal Pharmaka, Pero) are dropped rather than re-assigned; no new source is named anywhere.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Restrained, non-promotional register mirrors the ER, including the ER’s own closing judgement of a “modest, narrow” signal.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Doses, thresholds, and marker ranges are concrete while the lede states the limits of the evidence without discouraging framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe what was tested (“as tested in rheumatoid arthritis”) rather than instructing a course of action.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring targets are presented as table data; no imperative or prescriptive verb forms appear.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Cadence text (lines 759–762) uses noun phrases (“Baseline before the first dose; kidney and liver panels repeated at four weeks”) rather than recommendations.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to the monitoring table and the interaction gate where they name the actual measurand or drug class; the lede is jargon-free.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items, benefit tiers, and risk tiers are single clauses; the whole sheet is one screen of content per section.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for “you”/”your”; no matches.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional marker ranges, trough-level monitoring, and chemotype-specific preparation detail address an engaged, risk-aware reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Eight-marker baseline panel, four-week repeat, and 14-day pre-surgical window assume a reader prepared to bear that effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “ask your doctor” framing; the sheet expects chemotype literacy and laboratory follow-up.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede flags the narrow, commercially entangled evidence base, which is the decision-relevant weighting for an optimising reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears only in the canonical topic; no “anti-aging” occurrence in the file.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Formal register throughout (“acute kidney injury”, “neutropenia”, “denture stomatitis”, “topical gel”); no consumer-grade substitutes for route or event terms.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template byte-for-byte (lines 446, 492, 540, 569, 586, 611, 636, 640–642, 769).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	64 spans present: the 34 singleton variables plus 8 expanded marker rows (24 spans) and 6 expanded qualitative items.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff of head, CSS block, and footer against the template is empty apart from the populated page_title; no structural or stylistic drift.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped to a QRS variable is empty; the only empty tier (Risks → High) is governed by the more specific item 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels reproduce ER bold labels verbatim: “Standardised pentacyclic extract approach”, “Water-soluble quinic acid ester approach”, “Whole freeze-dried bark approach”.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol labels are verbatim; monitoring row labels reproduce the ER biomarker-table entries; no label is fabricated where the ER supplies one.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-text scan returns no emoji; the ER’s “⚠️ Conflicted” tag is rendered as plain “(conflicted)”.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to single-clause entries; no ER paragraph is carried across in full and no section duplicates ER prose.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2, immediately after <!doctype html> on line 1, and closes at line 14 before any other markup.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preceding caption text sits outside the block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values is repeated in the header, footer, or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, correctly, because it contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: cats_claw_2026-0911-0403_Opus_ER.md, matching the ER frontmatter filename.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge in QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0911-0542, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no context-window or tier qualifier appended.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: cats_claw_2026-0911-0403_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all ten keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Cat’s Claw for Health & Longevity - Quick Reference Sheet”; ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Cat’s Claw for Health & Longevity”, matching ER canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/11/2026, correctly derived from 2026-0911-0542.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Lines 434–438 compress all three Conclusion paragraphs: preparation reality, the joint-pain signal, the thin single-study record, and the safety/commercial caveat.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion sentence (ER lines 456–460), including “Safety reporting is reassuring but shallow” verbatim.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “painful, tender joints”, “antibody levels”, “day-to-day functioning” are all lay-comprehensible.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Refers only to “single small studies” with no trial name, year, or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	The ER’s 53.2% vs 24.1% and p = 0.044 figures are correctly omitted.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map one-to-one to the ER’s “Populations who should avoid Cat’s Claw” list (ER lines 303–309).
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete set of seven; none added, none dropped.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven discrete <li> elements inside the stop_items span (lines 572–581).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale stripped throughout: “— anti-rejection medicines” removed from the transplant item, “for whom no dosing or safety data exist” removed from the paediatric item.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(tacrolimus, cyclosporine)”, “(stage 3b or worse)”, the 45 mL/min/1.73 m² threshold, the 14-day surgical window, and the under-18 bound are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER contraindication list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven avoid-populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map to ER bullets at lines 287–299.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The ER’s first two bullets (narrow-therapeutic-index CYP3A4 substrates; boosted protease inhibitors) are correctly omitted because both appear in the stop gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven discrete <li> elements inside the caution_items span (lines 589–601).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All ER severity labels, mechanisms, and “Mitigation:” clauses are stripped; the hypertension bullet’s embedded animal-study citation is dropped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists retained throughout, e.g. “(simvastatin, midazolam, amlodipine, some chemotherapy agents)”, “(fexofenadine, loratadine)”, “(ibuprofen, naproxen)”, “(omeprazole)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction list uses no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 331–335.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The three preparation-and-dose approaches are the ER’s only decision-determining actionable choices; timing, half-life, and genotype bullets are secondary modifiers.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three distinct actionable aspects and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Doses match the ER exactly: 20–60 mg daily, 250–700 mg daily, 100 mg daily; each sub names the preparation and the trial context stated in the ER.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Joint pain, antibody levels, and immune/DNA repair markers are the only three time-to-effect facts the ER states (line 388).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches benefit tier: joint pain (High), antibody levels (Medium), immune and DNA repair markers (Speculative).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Values “Within 1 week”, “5 months”, “8 weeks” and their subs reproduce ER line 388 near-verbatim.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eight benefit entries correspond to ER Expected Benefits headings (ER lines 155–201).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 542–562).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-separated list of bare benefit headings; the ER’s magnitude paragraphs and trial descriptions are fully omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No ER parenthetical survives; the only parenthesis is “(conflicted)”, which carries the ER’s own evidence-conflict tag rather than parenthetical detail.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry at least one ER item, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven risk entries correspond to ER headings (ER lines 227–265).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present (lines 613–630).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare risk headings only; the ER’s case-report detail (creatinine 0.7 → 3.6 mg/dL, named antiretrovirals) is correctly absent.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	ER glosses such as “(a shortage of neutrophils…)” and “(keratinocytes)” are stripped; the only parenthesis is the ER’s “(conflicted)” tag on the CYP3A4 risk.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states no risk reaches High; risks_high carries style="display: none" with no empty-state text (line 613).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the biomarker table in ER Monitoring Protocol & Defining Success (ER lines 416–425).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER rows present in the same order, with targets and rationales reproduced verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 759–762 capture the full ER schedule: baseline, four weeks, twelve weeks, six-monthly, extra panel after co-medication change, plus trough timing.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER’s “Qualitative markers worth tracking” list (ER lines 429–434).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present in the same order, with the ER’s trailing rationale clauses trimmed.

Issues 11/09/2026 05:47

Pass rate 100.00%. No issues found.